Lawrence Honig is a Dementia and Cognitive Impairment Research physician affiliated with Columbia University. OpenAlex indexes 591 publications with 54,826 citations (h-index 103); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the findmyKOL directory.
Data verified 13 Oct 2026
Overview
Updated 13 Oct 2026
Lawrence Honig, M.D., PH.D., is affiliated with Columbia University. The public record shows 591 publications with 54,826 citations (h-index 103), centered on Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Parkinson's Disease Mechanisms and Treatments. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 13 companies, 5 NIH-funded awards (2000–2023).
- Most recent indexed publication: 2026 · Neurology
- Top research focus: Dementia and Cognitive Impairment Research
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 24 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 325.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease
Sponsor: Neurokine Therapeutics
- ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Sponsor: Mayo Clinic
Industry payments
Updated 13 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Biogen, Inc.Program year20259 payments$16,071openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year202513 payments$14,474openpaymentsdata.cms.gov ↗
- Beckman Coulter, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%SSRI33.7%Sertraline Hcl67%Paroxetine Hcl21%Escitalopram Oxalate12%Part D<11 patientsCholinesterase Inhibitor32.8%Galantamine Er52%Donepezil Hcl37%Rivastigmine12%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
5 NIH research awards on record, funded 2000–2023 per NIH RePORTER. The latest:
- Development of a stress kinase inhibitor therapeutic candidate for Alzheimer's Disease and related dementia
Neurokine Therapeutics, Llc
FY2023$1,218,076R44AG071388 - Development of a stress kinase inhibitor therapeutic candidate for Alzheimer's Disease and related dementia
Neurokine Therapeutics, Llc
FY2021$1,175,175R44AG071388 - Targeting Lewy Body Specific Pathology Using Biomarkers
Columbia University Health Sciences
FY2020$907,896U01NS100600
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- DYNAMIC CLASSIFICATION OF LATENT DISEASE PROGRESSION WITH AUXILIARY SURROGATE LABELS.
The annals of applied statistics
Article2026 - Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States.
Neurology. Clinical practice
Article2026
Most-cited works
by citation count (OpenAlex)- 01Diagnosis and management of dementia with Lewy bodiesArticle4,444 citations2017
- 02
- 03
- 04New insights into the genetic etiology of Alzheimer’s disease and related dementiasArticle2,460 citations2022
- 05Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseArticle1,957 citations2014
Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Similar KOLs
Other experts from the same institution or the same specialty.
Serge Przedborski, MD, PhD
Columbia University
Shonni Silverberg, MD
Columbia University
Jatin Vyas, MD, PhD
Columbia University
Pietro Canetta, MD
Columbia University
Paul Ridker, MD
Brigham and Women's Hospital
Edward Giovannucci, MD, ScD, MPH
Harvard T.H. Chan School of Public Health
Stephen Chanock, MD
National Cancer Institute (NCI)
Wei Zheng, MD, PhD, MPH
Vanderbilt University Medical Center